Use of18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma

American Journal of Roentgenology

Volumn 197, Issue 4, 2011, Pages 976-980

  Imsande, Heather M ^a   Davison, Jessica M ^a   Truong, Minh T ^a   Devaiah, Anand K ^a   Mercier, Gustavo A ^a   Ozonoff, Al J ^b   Subramaniam, Rathan M ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

18F FDG PET CT; Disease free survival; Head and neck; Non squamous cell carcinoma; Overall survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOVERSOL; IODOBENZOIC ACID DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; LIVER; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; HEAD AND NECK TUMOR; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TRIIODOBENZOIC ACIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053246722     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.4884     Document Type: Article

References (31)

1. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114:806-816 (Pubitemid 40344442)
2. Daley T, Darling M. Nonsquamous cell malignant tumours of the oral cavity: an overview. J Can Dent Assoc 2003; 69:577-582
3. Lin HW, Bhattacharyya N. Staging and survival analysis for nonsquamous cell carcinomas of the larynx. Laryngoscope 2008; 118:1003-1013 (Pubitemid 351787270)
4. Benchaou M, Lehmann W, Slosman DO, et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol 1996; 116:332-335 (Pubitemid 26126214)
5. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[F-18]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004; 59:1295-1300 (Pubitemid 38954050)
6. Rege SD, Chaiken L, Hoh CK, et al. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology 1993; 189:807-812 (Pubitemid 23354500)
7. Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[F-18] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20:1398-1404 (Pubitemid 34177448)
8. Pelizzo MR, Boschin IM, Toniato A, et al. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol 2008; 33:359-379
9. Greene FL, Page DL, Fleming ID, et al., eds. AJCC cancer staging manual, 6th ed. Chicago, IL: American Joint Committee on Cancer, 2002
10. RootsWeb. www.rootsweb.ancestry.com. Accessed August 15, 2009
11. vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17:3201-3206 (Pubitemid 29470652)
12. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004; 22:4357-4368 (Pubitemid 41185156)
13. Dresel S, Grammerstorff J, Schwenzer K, et al. [F-18]FDG imaging of head and neck tumours: comparison of hybrid PET and morphological methods. Eur J Nucl Med Mol Imaging 2003; 30:995-1003 (Pubitemid 37086942)
14. Slevin NJ, Collins CD, Hastings DL, et al. The diagnostic value of positron emission tomography (PET) with radiolabelled fluorodeoxyglucose (18F-FDG) in head and neck cancer. J Laryngol Otol 1999; 113:548-554 (Pubitemid 29308712)
15. Nowak B, Di Martino E, Janicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999; 38:312-318
16. Agarwal V, Branstetter BF, Johnson JT. Indications for PET/CT in the head and neck. Otolaryngol Clin North Am 2008; 41:23-49 (Pubitemid 351186576)
17. Paul SAM, Stoeckli SJ, Von Schulthess GK, Goerres GW. FDG PET and PET/CT for the detection of the primary tumour in patients with cervical non-squamous cell carcinoma metastasis of an unknown primary. Eur Arch Otorhinolaryngol 2007; 264:189-195 (Pubitemid 46011302)
18. Jabour BA, Choi Y, Hoh CK, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 1993; 186:27-35 (Pubitemid 23005462)
19. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro [F-18]-D-glucose. Cancer 1998; 82:2227-2234 (Pubitemid 28240830)
20. Vranjesevic D, Filmont JE, Meta J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002; 43:325-329 (Pubitemid 34208093)
21. Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AA. Prognostic factors of neck node metastasis. Clin Otolaryngol Allied Sci 1982; 7:185-192 (Pubitemid 12088842)
22. Kitagawa Y, Sadato N, Azuma H, et al. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J Nucl Med 1999; 40:1132-1137 (Pubitemid 29315503)
23. Davison JM, Ozonoff A, Imsande HM, Grillone GA, Subramaniam RM. Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake. Radiology 2010; 255:578-585
24. Roh JL, Ryu CH, Choi SH, et al. Clinical utility of F-18-FDG PET for patients with salivary gland malignancies. J Nucl Med 2007; 48:240-246
25. Suh C, Kang YK, Roh JL, et al. Prognostic value of tumor F-18-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 2008; 49:1783-1789
26. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999; 26:1363-1378 (Pubitemid 29467035)
27. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-850 (Pubitemid 23354506)
28. Lee JR, Madsen MT, Bushnel D, Menda Y. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun 2000; 21:685-690
29. Ramos CD, Erdi YE, Gonen M, et al. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 2001; 28:155-164
30. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009; 50(suppl 1):11S-20S
31. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50(suppl 1):122S-150S